http://www.pharmexec.com/pharmexec/Global+Report/Article/list/124 News, markets, and regulation in Europe, Asia, and South America. 2013-05-20T02:03:33Z http://www.pharmexec.com/pharmexec/Global+Report/The-Italians-Job/ArticleStandard/Article/detail/764157?contextCategoryId=124&ref=25 After his predecessor and countryman left the EMA in disgrace, Guido Rasi jumps in as executive director—with great challenges ahead. 2012-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102012/764157null XML http://www.pharmexec.com/pharmexec/Global+Report/IndustryGovt-RampD-Support-So-Far-So-Good/ArticleStandard/Article/detail/757956?contextCategoryId=124&ref=25 The EU's Innovative Medicines Initiative is helping to invigorate new drug development, but there are still many hurdles to tackle before its promise is realized. 2012-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062012/757956null XML http://www.pharmexec.com/pharmexec/Global+Report/Heres-to-a-Happier-New-Year/ArticleStandard/Article/detail/755080?contextCategoryId=124&ref=25 A turbulent year is ahead for European pharma, while EFPIA's Director General begins to rethink its approach to new science. 2012-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012012/755080null XML http://www.pharmexec.com/pharmexec/Global+Report/Europes-Transparency-Directive-Revisited/ArticleStandard/Article/detail/752328?contextCategoryId=124&ref=25 The effect on pharma of the EU's Transparency Directive has been overly constraining, but will the mooted revisions offer any room to maneuver? 2011-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752328null XML http://www.pharmexec.com/pharmexec/Global+Report/Europe-Tackles-Advertising-in-Disguise-Fears/ArticleStandard/Article/detail/747601?contextCategoryId=124&ref=25 The EC's latest proposals have thrown water on Europe's firey Direct-to-Consumer advertising debate. But is it enough to keep the flames at bay? 2011-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747601null XML http://www.pharmexec.com/pharmexec/Global+Report/Does-a-German-Launch-Make-Sense/ArticleStandard/Article/detail/747588?contextCategoryId=124&ref=25 Will the structure and ambiguity of Germany's new medicines pricing system bring a halt to new drug launches in Europe's largest market? 2011-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747588/Germany-small_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452011/747588null XML http://www.pharmexec.com/pharmexec/Global+Report/Sweden-Setting-the-Pace-for-Global-Pharma/ArticleStandard/Article/detail/744348?contextCategoryId=124&ref=25 Garbo gets it ... 2011-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422011/744348null XML http://www.pharmexec.com/pharmexec/Global+Report/Emerging-MarketsThe-Myths-and-Traps/ArticleStandard/Article/detail/744345?contextCategoryId=124&ref=25 Success in the emerging markets depends significantly on navigating the myths and mental traps. 2011-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422011/744345/mousetrap-web-small_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Global+Report/Front-and-Center-in-the-Fight-against-TB/ArticleStandard/Article/detail/739260?contextCategoryId=124&ref=25 Pharm Exec talks to Dr. Mel Spigelman, President and CEO of the TB Alliance, about the organization's tuberculosis priorities. 2011-09-01T04:00:00Z XML http://www.pharmexec.com/pharmexec/Global+Report/The-Power-of-Product-Development-Partnership/ArticleStandard/Article/detail/739264?contextCategoryId=124&ref=25 Can cooperative ties between Big Pharma, NGOs, government, and international organizations pay the freight in making the fight against neglected diseases a permanent fix in global health? 2011-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372011/739264/PDP-thumb_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Global+Report/Innovating-Around-Innovation/ArticleStandard/Article/detail/739259?contextCategoryId=124&ref=25 Richard Barker, former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science. 2011-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372011/739259/richard+barker_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372011/739259null XML http://www.pharmexec.com/pharmexec/Global+Report/Should-the-US-Gamble-with-Risk-Sharing/ArticleStandard/Article/detail/739261?contextCategoryId=124&ref=25 Especially when payers come to the table holding the best cards — leaving industry second-guessing its strategy. 2011-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372011/739261/casino-chips.crop_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Global+Report/What-the-2011-Census-of-India-Reveals-for-Pharma/ArticleStandard/Article/detail/730201?contextCategoryId=124&ref=25 What India's latest census tells us about current and future pharma opportunities. 2011-07-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282011/730201/India-flag_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282011/730201null XML http://www.pharmexec.com/pharmexec/Global+Report/12th-Annual-Pharm-Exec-50/ArticleStandard/Article/detail/719596?contextCategoryId=124&ref=25 Who's taken this year's top spot? Find out in Pharm Exec's annual run-down of the world's Top 50 pharma companies. 2011-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/192011/719596/phara50-cropped_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/192011/719596/phara50_flash.jpg XML http://www.pharmexec.com/pharmexec/Technology/Out-of-Control/ArticleStandard/Article/detail/719599?contextCategoryId=124&ref=25 The pharmaceutical industry needs to use new and better data to accurately measure how much it is willing to invest in avoiding plan control 2011-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/192011/719599null XML http://www.pharmexec.com/pharmexec/Global+Report/Dallis-Formula-Fails-the-Efficacy-Test/ArticleStandard/Article/detail/716291?contextCategoryId=124&ref=25 EU leadership on pharma policy leaves many wondering of the right man is at the helm 2011-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/162011/716291null XML http://www.pharmexec.com/pharmexec/Global+Report/China-Business-as-UNusual/ArticleStandard/Article/detail/707516?contextCategoryId=124&ref=25 If there is one market that requires a click on the 'refresh' button, it's China. General Biologic provides a snapshhot of what's ahead for Big Pharma in the country 2011-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072011/707516/china_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072011/707516null XML http://www.pharmexec.com/pharmexec/Global+Report/Growing-Stronger-After-the-Storm/ArticleStandard/Article/detail/707510?contextCategoryId=124&ref=25 To manage through a resource-constrained environment, it is essential to get the most out of procurement planning 2011-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072011/707510/cloud2_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072011/707510null XML http://www.pharmexec.com/pharmexec/Global+Report/The-Sum-of-All-His-Parts-Career-Reflections-of-Eur/ArticleStandard/Article/detail/700435?contextCategoryId=124&ref=25 Outgoing EMA Director Thomas Lonngren discusses a decade at the helm of Europe's top regulatory office 2010-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512010/700435/The-Sum-of-All-His-Parts-Career-Re_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512010/700435null XML http://www.pharmexec.com/pharmexec/Global+Report/China-2020-Walled-In-No-More/ArticleStandard/Article/detail/700452?contextCategoryId=124&ref=25 Pharma sets the pace for China's ambitious new innovation agenda 2010-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512010/700452/China-2020-Walled-In_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512010/700452null XML http://www.pharmexec.com/pharmexec/Global+Report/Japan-The-Real-Emerging-Market/ArticleStandard/Article/detail/695696?contextCategoryId=124&ref=25 With all the money and momentum focused on medicines in emerging markets, it may be time to take a closer look at business opportunities in this more familiar neighbor to the East 2010-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/472010/695696/Japan_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/472010/695696null XML http://www.pharmexec.com/pharmexec/Global+Report/Euro-Soul-Searching-on-Competition/ArticleStandard/Article/detail/690969?contextCategoryId=124&ref=25 A report by the European Commission aimed at exploring patent exploitation by Big Pharma winds up generating more angst than answers 2010-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422010/690969null XML http://www.pharmexec.com/pharmexec/Global+Report/UK-Pharmacies-Dealing-with-Drug-Shortages/ArticleStandard/Article/detail/625140?contextCategoryId=124&ref=25 With a weak pound being outpaced by the euro, many hospitals are sending drugs to the Continent for higher profits. What can NHS do to stop this practice? 2009-09-09T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372009/625140null HTML http://www.pharmexec.com/pharmexec/Global/Last-NICE-Word-on-Alzheimers-Meds/ArticleStandard/Article/detail/609626?contextCategoryId=124&ref=25 UK Health Institute leaves guidance unchanged in case against Eisai and Pfizer; more research on NICE methodology needed. 2009-07-08T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282009/609626null HTML http://www.pharmexec.com/pharmexec/Columns/Understanding-the-New-World-Order-of-Emerging-Mark/ArticleStandard/Article/detail/604394?contextCategoryId=124&ref=25 Pharma is wrestling to understand the emerging markets will be the engine of growth for future sales. 2009-06-17T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/252009/604394null HTML http://www.pharmexec.com/pharmexec/Global/UK-Group-Recommends-Path-to-Building-Trust/ArticleStandard/Article/detail/590842?contextCategoryId=124&ref=25 A new report by the Royal College of Physicians breaks down the reasons why patients are disillusioned about access to medicines, and documents a steady growth in the lack of trust between industry and the NHS. More importantly, it gives recommendations on how to solve the problems. 2009-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/142009/590842null HTML http://www.pharmexec.com/pharmexec/Global+Report/Reforms-Offer-Good-News-for-Trade/ArticleStandard/Article/detail/580039?contextCategoryId=124&ref=25 EC proposal loosens restrictions on drug packaging and information dissemination. 2009-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062009/580039null XML http://www.pharmexec.com/pharmexec/Global+Report/Animal-Humanity/ArticleStandard/Article/detail/570129?contextCategoryId=124&ref=25 The new EU directive looks to reduce, refine, and eventually replace animal testing 2008-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/492008/570129null XML http://www.pharmexec.com/pharmexec/Global+Report/Cash-Flow-Woes-in-EU/ArticleStandard/Article/detail/566069?contextCategoryId=124&ref=25 In Europe, it's different strokes for different folks at the top regulatory agencies 2008-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/462008/566069null XML http://www.pharmexec.com/pharmexec/Global+Report/Open-For-Debate/ArticleStandard/Article/detail/557672?contextCategoryId=124&ref=25 Tensions mount as stakeholders in the UK health industry attempt to work out drug cost problems 2008-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/412008/557672null XML http://www.pharmexec.com/pharmexec/Global+Report/Doing-More-With-Less/ArticleStandard/Article/detail/548244?contextCategoryId=124&ref=25 In order to take a big step forward, GSK looks to employ smaller licensing deals and business units 2008-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372008/548244null XML http://www.pharmexec.com/pharmexec/Global+Report/Jumping-the-Gun/ArticleStandard/Article/detail/533841?contextCategoryId=124&ref=25 Britain's new approach to drug pricing isn't as bad as the industry feared. 2008-08-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322008/533841null XML http://www.pharmexec.com/pharmexec/Global+Report/Tightening-the-Chain/ArticleStandard/Article/detail/523685?contextCategoryId=124&ref=25 EU makes plans to police its supply chain 2008-06-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242008/523685null XML http://www.pharmexec.com/pharmexec/Global+Report/British-Biotech-Blues/ArticleStandard/Article/detail/507982?contextCategoryId=124&ref=25 Can ceasing trade sales and finding funding help UK biotechs became an industry in their own right? 2008-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/152008/507982null XML http://www.pharmexec.com/pharmexec/Global+Report/Fire-and-NICE/ArticleStandard/Article/detail/501200?contextCategoryId=124&ref=25 UK agency takes the heat for slow evaluations and failing to consider societal benefits of new drugs 2008-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102008/501200null XML http://www.pharmexec.com/pharmexec/Global+Report/Wholesale-Change-UK-Responds-to-the-Single-Supplie/ArticleStandard/Article/detail/490701?contextCategoryId=124&ref=25 Will the sole-wholesaler approach mean higher costs for NHS? 2008-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072008/490701null XML http://www.pharmexec.com/pharmexec/Global+Report/Oxfam-Points-Finger/ArticleStandard/Article/detail/483066?contextCategoryId=124&ref=25 Pharma defends itself against claims made in charity's report on drug access for the world's poor 2008-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/022008/483066null XML http://www.pharmexec.com/pharmexec/Current+Issue/Inviting-Innovation/ArticleStandard/Article/detail/476124?contextCategoryId=124&ref=25 One of industry's main complaints is that delaying the introduction of new medicines is a particularly simple way of saving money 2007-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/482007/476124null XML http://www.pharmexec.com/pharmexec/Current+Issue/India-vs-China/ArticleStandard/Article/detail/469185?contextCategoryId=124&ref=25 Will CROs continue to operate in India, or will Novartis' pullout send them farther East? 2007-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/442007/469185null XML http://www.pharmexec.com/pharmexec/Current+Issue/Some-Alzheimers-Patients-Left-Behind/ArticleStandard/Article/detail/463116?contextCategoryId=124&ref=25 A landmark court case in the United Kingdom has left Alzheimer's patients with mild to moderate disease unable to receive any of the three drugs that might help them—Aricept (donepezil), Reminyl (galantamine), and Exelon (rivastigmine). Eisai and Pfizer, which make and market Aricept, had challenged the ruling made last year by the National Institute for Clinical Excellence that the drugs should be prescribed only to patients in the later stages of the disease. They were granted a judicial review—the first time one of NICE's decisions had been challenged in this way—and while the judge upheld one part of the challenge, the other two parts were dismissed and NICE's guidance stands. 2007-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/402007/463116null XML http://www.pharmexec.com/pharmexec/Current+Issue/Incentives-Incense-Industry-in-UK/ArticleStandard/Article/detail/455798?contextCategoryId=124&ref=25 The Association of the British Pharmaceutical Industry is challenging the UK government over the financial incentives being offered by the Department of Health (DH) to encourage doctors to switch patients from on-patent medicines to specific generic alternatives. ABPI believes the way the incentives are structured contravenes EU law—if pharma companies were to offer similar payments, they would be in serious trouble. 2007-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372007/455798null XML http://www.pharmexec.com/pharmexec/Global+Report/Make-Resistance-Futile/ArticleStandard/Article/detail/446935?contextCategoryId=124&ref=25 Scare stories about antibiotic-resistant bacteria are all too common in the mass media these days. In the United Kingdom alone, the number of deaths from methicillin-resistant Staphylococcus aureus almost doubled between 2001 and 2005 to more than 2,000. The situation with Clostridium difficile is even worse, with UK deaths tripling to almost 4,000 over the same period. The big problem is that the incidence is growing, yet few antibiotics are being developed that will be able to kill the resistant bacteria. 2007-07-30T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/312007/446935null XML http://www.pharmexec.com/pharmexec/Global+Report/Five-Year-Survivor-European-Edition/ArticleStandard/Article/detail/442278?contextCategoryId=124&ref=25 Says Roche UK CEO John Melville: "There is little difference in the incidence of cancer, in broad terms, across Europe, but cancer survival is very different" 2007-07-03T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/292007/442278null XML http://www.pharmexec.com/pharmexec/Global+Report/Global-Report-Single-Source-Supply/ArticleStandard/Article/detail/429154?contextCategoryId=124&ref=25 Stakeholders worry that less competition among drug suppliers in the United Kingdom could mean higher prices and a bigger bill for the National Health Service 2007-06-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/212007/429154null XML http://www.pharmexec.com/pharmexec/Global+Report/Global-Report-Pure-and-Simple/ArticleStandard/Article/detail/423213?contextCategoryId=124&ref=25 It's not always obvious just who is reponsible for the various steps of pharmacovigilance. 2007-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/182007/423213null XML http://www.pharmexec.com/pharmexec/Global+Report/Global-Report-Ready--Set-/ArticleStandard/Article/detail/408485?contextCategoryId=124&ref=25 The UK has benefited from the stem-cell debate in the US. Several scientists have fled to Europe's more favorable regulatory stance. 2007-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/092007/408485null XML http://www.pharmexec.com/pharmexec/Global+Report/Global-Report-Under-One-Roof/ArticleStandard/Article/detail/401663?contextCategoryId=124&ref=25 The UK's 'unsystematic' healthcare structure is getting a makeover. It includes a new single body to oversee drug development, and potential incentives for pharma—if it plays nice. 2007-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/052007/401663null XML http://www.pharmexec.com/pharmexec/Global+Report/Global-Report-No-Satisfaction/ArticleStandard/Article/detail/395592?contextCategoryId=124&ref=25 In Germany, the eight million richest citizens contribute nothing to the system that pays for the remaining 70 million insured people. 2007-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/012007/395592null XML http://www.pharmexec.com/pharmexec/Global+Report/Global-Report-Not-So-NICE/ArticleStandard/Article/detail/389282?contextCategoryId=124&ref=25 Even when NICE has said that drugs should be available to anyone who needs them, patients still have to convince their Primary Care Trusts. 2006-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/482006/389282null XML http://www.pharmexec.com/pharmexec/Global+Report/Global-Report-Bout-Time/ArticleStandard/Article/detail/382535?contextCategoryId=124&ref=25 Pfizer says it is trying to stamp out counterfeiting by consolidating under one drug distributor. Critics think otherwise. 2006-11-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/442006/382535null XML http://www.pharmexec.com/pharmexec/Global+Report/Global-Report-Please-Come-Back/ArticleStandard/Article/detail/378060?contextCategoryId=124&ref=25 A new European collaboration of biotech, pharma, academia, and government takes up the challenge of boosting R&D. 2006-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/412006/378060null XML http://www.pharmexec.com/pharmexec/Global+Report/Global-Report-Break-with-Tradition/ArticleStandard/Article/detail/369269?contextCategoryId=124&ref=25 Public revulsion at animal-rights extremists is damaging their cause. The majority of people deem the worst offenders to be terrorists. 2006-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/362006/369269null XML http://www.pharmexec.com/pharmexec/Columns/Global-Report-People-Problems/ArticleStandard/Article/detail/333309?contextCategoryId=124&ref=25 Staggering doses in clinical trials may prevent large numbers of people from experiencing serious side effects. But it presents practical and ethical dilemmas, such as determining who is going to be first in line for their dose. 2006-06-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/232006/333309null XML http://www.pharmexec.com/pharmexec/Columns/Global-Report-A-Hope-and-a-Payer/ArticleStandard/Article/detail/322954?contextCategoryId=124&ref=25 One health insurance company in The Netherlands is offering doctors a financial incentive to prescribe generic statins and proton pump inhibitors. Doctors and patients complained, but a court upheld the practice. 2006-05-01T04:00:00Z XML http://www.pharmexec.com/pharmexec/Columns/Global-Report-Chemicals-Legislation-in-Europe/ArticleStandard/Article/detail/310974?contextCategoryId=124&ref=25 Drugs are not directly addressed in Europe's new legislation for chemicals. But they'll be affected, because chemicals are used in drug manufacturing. 2006-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102006/310974/PE_MarCVR_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Columns/Global-Report-Moving-Towards-Generic-Biologics/ArticleStandard/Article/detail/301751?contextCategoryId=124&ref=25 In Europe, seven of the top-10 injectible drugs are biologics. Generic versions could be priced 25 to 40 percent lower than prescriptions. 2006-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/052006/301751/PE_FEB_TN_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Global+Report/Global-Report-The-UKs-New-Code-of-Conduct/ArticleStandard/Article/detail/282479?contextCategoryId=124&ref=25 Serious offenders of the new Association of the British Pharmaceutical Industry's Code of Practice can be "named and shamed" with adverts in the trade press. Details of breaches by companies will be posted online. 2006-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/022006/282479/PE_TN_0106_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Global+Report/Global-Report-Wanted-Attention/ArticleStandard/Article/detail/256548?contextCategoryId=124&ref=25 The biggest threat to the success of polio eradication is Nigeria, where the immunization program was suspended on religious grounds in some parts of the country in 2003 and 2004. 2005-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/502005/256548/PE1205_TN_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Global+Report/Global-Report-Drug-Evaluation-in-the-UK/ArticleStandard/Article/detail/197793?contextCategoryId=124&ref=25 Genentech and Biogen's MabThera has been awaiting NICE appraisal for three years. Merck KGaA's Erbitux has waited two-and-a-half years. A ruling on AstraZeneca's Arimidex isn't expected for more than a year. 2005-11-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/472005/197793/110105_pe_cvr_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Global+Report/Global-Report-Animal-Attacks/ArticleStandard/Article/detail/187078?contextCategoryId=124&ref=25 UK courts are affirming the belief that medical research and drug development have made a huge contribution to people's quality of life, and that a small but vital part of that work involves the use of animals. 2005-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422005/187078/PE_TN_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Current+Issue/Global-Report-Kids-R-EU/ArticleStandard/Article/detail/177962?contextCategoryId=124&ref=25 If the legislation passes, companies will be rewarded with a six-month extension of market exclusivity if they conduct pediatric trials. And under the proposal, companies that fail to comply can be penalized. 2005-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/362005/177962/PE_TN_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Current+Issue/Global-Report-Big-Disadvantage/ArticleStandard/Article/detail/175697?contextCategoryId=124&ref=25 SPCs extend a drug's basic patent protection for up to five years, to take into account the time that may have lapsed between the filing of a patent application and the granting of market authorization. 2005-08-01T04:00:00Z XML http://www.pharmexec.com/pharmexec/Current+Issue/Global-Report-Still-Waiting/ArticleStandard/Article/detail/170707?contextCategoryId=124&ref=25 Traders say parallel distribution of drugs generates savings for patients. Industry says it creates more profits for traders, leaving pharma with less R&D funding. 2005-07-01T04:00:00Z XML http://www.pharmexec.com/pharmexec/Global+Report/A-Tall-Order/ArticleColumn/Article/detail/21510?contextCategoryId=124&ref=25 The past few years have seen a steady increase in new medicines being discovered and developed in the United States and a decrease in those from Europe, where it takes much longer for new medicines to become available to patients. In some cases, it takes medicines three or four years from their approval date to reach the market in all European Union member states. So, in March 2001, the European Commission appointed a high-level group to address those issues on a Europe-wide basis, involving all the different member states and stakeholders. 2002-06-01T04:00:00Z XML http://www.pharmexec.com/pharmexec/Global+Report/Business-as-Usual/ArticleStandard/Article/detail/2228?contextCategoryId=124&ref=25 The September 11 attacks on the United States caused pharma shares to fall along with others, but as investors switched to safe stocks, considered less susceptible to cyclical consumer trends, they rebounded. On September 12, broker WestLB Panmure raised its recommendation of the pharma sector from "neutral" to "outperform," favoring Sanofi-Synthelabo, Novo-Nordisk, Shire Pharmaceuticals, and GSK. 2001-11-01T05:00:00Z XML